首页> 外文期刊>Clinical therapeutics >Effectiveness and Cost-Effectiveness of Facilitated Percutaneous Coronary Intervention Compared with Primary Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction Transferred from Community Hospitals
【24h】

Effectiveness and Cost-Effectiveness of Facilitated Percutaneous Coronary Intervention Compared with Primary Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction Transferred from Community Hospitals

机译:社区医院转诊ST段抬高型心肌梗死患者经皮冠状动脉介入治疗与原发性经皮冠状动脉介入治疗的有效性和成本效益比较

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Primary percutaneous coronary intervention ([PCI], percutaneous transluminal coronary angioplasty + stenting) for ST-segment elevation myocardial infarction (STEMI) is regarded as superior to fibrinolysis even if it means that patients need to be transferred from one center to another to undergo the procedure, However, this inevitable delay between symptom onset and PCI, caused by the time required to travel, might increase the occurrence of cardiac events. A hybrid method called facilitated PCI uses fibrinolysis and/or glycoprotein (GP) IIb/IIIa inhibitors before transfer to a tertiary medical center where urgent PCI might be performed. This approach, however, has not been systematically evaluated. Objective: The purpose of this study was to compare the effectiveness (combined end point of in-hospital mortality, reinfarction, stroke, or emergency revascu-larization) and cost-effectiveness of utilizing a bolus thrombolytic agent with GP Ilb/IIIa inhibitor followed by transfer to a tertiary institution for facilitated PCI or standard of care transfer without primary PCI drugs among patients presenting to a community hospital with STEMI. Methods: This was a prospective, single-center, cohort study comprising data from STEMI patients transferred from community hospitals to Hartford Hospital, Hartford, Connecticut, from the years 2000 to 2003. At the time of analysis, patients receiving primary PCI were matched (1:1) with those receiving facilitated PCI, utilizing propensity scores to assure similar demographics. The combined incidence of major adverse cardiac end points (MACE) and total hospital costs was compared between groups. Non-parametric bootstrapping was conducted to calculate CIs for the incremental cost-effectiveness ratio and generate a quadrant analysis. Results: Based on 254 propensity score-matched patients (127 facilitated PCI and 127 primary PCI), in-hospital MACE and total hospital costs were reduced by 61.3% and US dollar4563 (2005), respectively, in patients receiving facilitated compared with primary PCI (P = 0.021 and P = NS, respectively). Patients receiving facilitated PCI were more likely to have target lesion Thrombolysis in Myocardial Infarction (TIMI) III (normal) blood flow on cardiac catheterization than those receiving primary PCI (49.6% vs 30.7%; ? = 0.002). However, the rate of TIMI bleeding was similar in both groups (21.3% in the facilitated PCI group vs 18.9% in the primary PCI group). Nonsignificant reductions were observed in both intensive care unit (ICU) and total length of stay (LOS) (0.8 day and 1.0 day, respectively) compared with the primary PCI group. Bootstrap analysis revealed that of 25,000 samplings, facilitated PCI would likely be both more effective and less costly 94.6% of the time.
机译:背景:ST段抬高型心肌梗死(STEMI)的主要经皮冠状动脉介入治疗([PCI],经皮腔内冠状动脉成形术+支架置入术)被认为优于纤维蛋白溶解,即使这意味着患者需要从一个中心转移到另一个中心再到另一个进行该过程,但是,由于行进所需的时间而导致的症状发作和PCI之间不可避免的延迟可能会增加心脏事件的发生。一种称为便利PCI的混合方法,在转移到可能需要紧急PCI的三级医疗中心之前,先使用纤维蛋白溶解和/或糖蛋白(GP)IIb / IIIa抑制剂。但是,这种方法尚未得到系统的评估。目的:本研究的目的是比较使用推注溶栓剂和GP Ilb / IIIa抑制剂然后再使用推注溶栓剂的有效性(院内死亡率,再梗塞,中风或紧急血管再通的合并终点)和成本效益。转移到第三级机构,以便在有STEMI的社区医院就诊的患者中无需初级PCI药物就可以进行便利的PCI或标准护理。方法:这是一项前瞻性,单中心,队列研究,包括从2000年至2003年从社区医院转移到康涅狄格州哈特福德的哈特福德医院的STEMI患者的数据。在分析时,对接受原发性PCI的患者进行了匹配( 1:1)与接受便利PCI的患者一样,利用倾向得分来确保相似的人口统计。比较两组之间主要不良心脏终点(MACE)的发生率和总住院费用。进行了非参数自举以计算增量成本效益比的CI并生成象限分析。结果:基于254名倾向评分匹配的患者(127例辅助PCI和127例主PCI),与主PCI相比,接受辅助治疗的患者的住院MACE和总住院费用分别降低了61.3%和4563美元(2005年) (分别为P = 0.021和P = NS)。与接受原发性PCI的患者相比,接受辅助PCI的患者在进行心脏导管插入术时更有可能在心肌梗塞(TIMI)III(正常)血流中发生靶病变溶栓(49.6%vs 30.7%;? = 0.002)。但是,两组的TIMI出血率相似(便利PCI组为21.3%,而初级PCI组为18.9%)。与初级PCI组相比,重症监护病房(ICU)和总住院时间(LOS)(分别为0.8天和1.0天)均未见明显减少。 Bootstrap分析显示,在25,000个采样中,便利的PCI可能会更有效且成本更低,达到94.6%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号